コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 s usual care in adults with covid-19 related hypoxemic respiratory failure.
2 ients with coronavirus diseases 2019-related hypoxemic respiratory failure.
3 istress syndrome on day 1 and day 2 of acute hypoxemic respiratory failure.
4 (n = 51, 82%) was the main etiology of acute hypoxemic respiratory failure.
5 tients were placed on VV ECMO for refractory hypoxemic respiratory failure.
6 -aged patients and is associated with severe hypoxemic respiratory failure.
7 d conditions and presented with acute severe hypoxemic respiratory failure.
8 Mechanical ventilation was begun for hypoxemic respiratory failure.
9 al fibrosis with decreasing lung volumes and hypoxemic respiratory failure.
10 is established therapy for term infants with hypoxemic respiratory failure.
11 th high hospital mortality for patients with hypoxemic respiratory failure.
12 oxygen therapy alone in patients with acute hypoxemic respiratory failure.
13 aled nitric oxide in premature newborns with hypoxemic respiratory failure.
14 ailure patients, and 86% in 57 patients with hypoxemic respiratory failure.
15 d nitric oxide in the premature newborn with hypoxemic respiratory failure.
16 nt for intensive care in children with acute hypoxemic respiratory failure.
17 ane oxygenation in term neonates with severe hypoxemic respiratory failure.
18 n clinical outcome in neonatal patients with hypoxemic respiratory failure.
19 tric oxide (NO) in four patients with severe hypoxemic respiratory failure.
20 of ventilator support in children with acute hypoxemic respiratory failure.
21 years requiring hospital admission for acute hypoxemic respiratory failure.
22 pitalized adults with COVID-19-related acute hypoxemic respiratory failure.
23 is increasingly used in patients with acute hypoxemic respiratory failure.
24 drome (30.3% vs 8.6%; P = .004) or prolonged hypoxemic respiratory failure (39.4% vs 11.4%; P = .001)
26 lar monocyte and macrophage subsets in acute hypoxemic respiratory failure (AHRF) are poorly understo
27 ndard of care for patients with severe acute hypoxemic respiratory failure (AHRF) caused by COVID-19
28 arch into critically ill patients with acute hypoxemic respiratory failure (AHRF) is growing, how thi
29 extubation readiness in patients with acute hypoxemic respiratory failure (AHRF) may not reflect lun
30 isease-19 (COVID-19) pneumonia induced acute hypoxemic respiratory failure (AHRF), but predictors of
31 o improve oxygenation in children with acute hypoxemic respiratory failure (AHRF), but their roles in
32 s receiving this drug for treatment of acute hypoxemic respiratory failure (AHRF), in order to determ
33 Intubation is a common procedure in acute hypoxemic respiratory failure (AHRF), with minimal evide
35 d patients without hypercapnia who had acute hypoxemic respiratory failure and a ratio of the partial
36 r the treatment of large patients with acute hypoxemic respiratory failure and asymmetric lung diseas
38 s recommended as initial treatment for acute hypoxemic respiratory failure and is widely applied in p
39 genation in near-term and term newborns with hypoxemic respiratory failure and persistent pulmonary h
40 support in near-term and term newborns with hypoxemic respiratory failure and persistent pulmonary h
41 brane oxygenation is needed in neonates with hypoxemic respiratory failure and pulmonary hypertension
42 severe end of this spectrum may present with hypoxemic respiratory failure and pulmonary infiltrates,
43 ng noninvasive ventilation for de novo acute hypoxemic respiratory failure, and a high expired tidal
44 sing for making advances in pneumonia, acute hypoxemic respiratory failure, and acute respiratory dis
45 nger, required assisted ventilation, and had hypoxemic respiratory failure as defined by an oxygenati
46 l of nonintubated patients with COVID-19 and hypoxemic respiratory failure, daily APP of 6 hours show
47 y reveals diffuse bilateral infiltrates, and hypoxemic respiratory failure develops despite appropria
48 apy in children aged 1 to 4 years with acute hypoxemic respiratory failure did not significantly redu
49 h-flow nasal cannula is widely used in acute hypoxemic respiratory failure due to coronavirus disease
50 sk of endotracheal intubation in adults with hypoxemic respiratory failure due to covid-19 but probab
51 espiratory support among patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia.
57 who require mechanical ventilation for acute hypoxemic respiratory failure, further reduction in tida
58 bation.Conclusions: As compared with HFNC in hypoxemic respiratory failure, helmet NIV improves oxyge
59 in ABI patients, including among those with hypoxemic respiratory failure, highlighting potential op
60 ention groups for the COVID-19 patients with hypoxemic respiratory failure; however, more evidence is
61 g the efficiency of clinical trials in acute hypoxemic respiratory failure (HRF) depends on enrichmen
62 ng noninvasive ventilation for de novo acute hypoxemic respiratory failure (i.e., not due to exacerba
63 cillatory ventilation for treatment of acute hypoxemic respiratory failure in children with diffuse a
65 xygen (HFNO) have been recommended for acute hypoxemic respiratory failure in patients with COVID-19.
68 e of high mortality rate among patients with hypoxemic respiratory failure in the intervention arm (8
69 onary diffusion capacity in ICU survivors of hypoxemic respiratory failure included in this one-year
73 annula (HFNC) therapy in patients with acute hypoxemic respiratory failure is to not delay intubation
74 common reasons for admission to the ICU were hypoxemic respiratory failure leading to mechanical vent
77 s used ECLS for 100 adults with severe acute hypoxemic respiratory failure (n = 94): paO2/FiO2 ratio
78 n (NIV) are used for the management of acute hypoxemic respiratory failure.Objectives: Physiological
79 s receiving mechanical ventilation for acute hypoxemic respiratory failure, of a planned sample size
80 ng invasive mechanical ventilation for acute hypoxemic respiratory failure or after thoracic surgery
82 acute respiratory infection had more severe hypoxemic respiratory failure (PaO2/FIO2: 106 [66, 160]
83 ad undergone abdominal surgery and developed hypoxemic respiratory failure (partial oxygen pressure <
86 atients with COVID-19 and moderate to severe hypoxemic respiratory failure (ratio of partial pressure
87 admission to the intensive care unit due to hypoxemic respiratory failure requiring mechanical venti
88 e, nonintubated inpatients with COVID-19 and hypoxemic respiratory failure requiring oxygen supplemen
89 tions, was able to support the same level of hypoxemic respiratory failure secondary to acute lung in
90 c signature in children with pediatric acute hypoxemic respiratory failure. Seventy-four immunocompet
91 ents developed inspiratory stridor and acute hypoxemic respiratory failure shortly after the stent wa
92 als but in a higher percent of patients with hypoxemic respiratory failure than reported in these tri
93 stress syndrome (ARDS) is severe, noncardiac hypoxemic respiratory failure that carries a substantial
94 distress syndrome (ARDS) is a form of severe hypoxemic respiratory failure that is characterized by i
96 -Vt ventilation strategies in ARDS and acute hypoxemic respiratory failure, the posterior probability
97 Objectives: To measure, in patients with hypoxemic respiratory failure, the probability of invasi
99 judication in three cohorts of patients with hypoxemic respiratory failure (training, internal valida
101 lysis of trials of adult patients with acute hypoxemic respiratory failure, treatment with noninvasiv
102 cardiovascular conditions and intubation for hypoxemic respiratory failure were associated with a hig
105 e hospital mortality for patients with acute hypoxemic respiratory failure who failed NPPV was 64%.
106 on, pulmonary hypertension, and severe acute hypoxemic respiratory failure who underwent endotracheal
107 t of eosinophilic lung disease develop acute hypoxemic respiratory failure with a rapid response to t
108 ritical illness syndrome consisting of acute hypoxemic respiratory failure with bilateral pulmonary i
109 apy in children aged 1 to 4 years with acute hypoxemic respiratory failure without bronchiolitis is u